These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3085875)

  • 1. [Proposal for a new synthetic inhibitor of C1 esterase, methyl-2 thiazoline carbamic ester-3 spirobutenolide: enzyme and electron studies].
    Ollier-Hartmann MP; Rocher JP; Tinland B; Hartmann L; Paris J
    C R Acad Sci III; 1986; 302(10):369-74. PubMed ID: 3085875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular interaction between synthetic spirobutenolides and C1 esterase normal inhibitor].
    Bador P; Ollier-Hartmann MP; Paris J; Hartmann L
    C R Acad Sci III; 1986; 303(3):55-8. PubMed ID: 3093005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New preparation method of C1 esterase for the dosage of its plasma inhibitor].
    Gozin D; Ollier-Hartmann MP; Lerable J; Hartmann L; Soulier JP
    Biomed Pharmacother; 1983; 37(5):228-30. PubMed ID: 6607074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum C1-esterase inhibitor (C1INH) levels in normal adults.
    Ongaro G; Calabrò A; Panunzio MT
    Quad Sclavo Diagn; 1982 Mar; 18(1):104-13. PubMed ID: 6818608
    [No Abstract]   [Full Text] [Related]  

  • 5. Changes of C1 esterase inhibitor, alpha2 globulin and sedimentation rate after severe brain injury.
    Spiteri D; Viola L; Allegretti De Lista G; Galloro F; Schisano G
    Acta Neurol (Napoli); 1983 Dec; 5(6):420-5. PubMed ID: 6199953
    [No Abstract]   [Full Text] [Related]  

  • 6. C1 esterase-inhibitor concentrate prevents hypotension from plasma-protein solutions.
    Van der Starre P; Sinclair D; Damen J; Brummelhuis H
    N Engl J Med; 1979 May; 300(22):1276. PubMed ID: 311888
    [No Abstract]   [Full Text] [Related]  

  • 7. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase.
    Tamura Y; Hirado M; Okamura K; Minato Y; Fujii S
    Biochim Biophys Acta; 1977 Oct; 484(2):417-22. PubMed ID: 143965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel design principle validated: glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent.
    Somsák L; Nagy V; Vidal S; Czifrák K; Berzsényi E; Praly JP
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5680-3. PubMed ID: 18793852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1.
    Tenner AJ; Frank MM
    J Immunol; 1986 Jul; 137(2):625-30. PubMed ID: 3722818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of 3H-spiro[benzofuran-2,1'-cyclohexane] derivatives from naturally occurring filifolinol and their classical complement pathway inhibitory activity.
    Useglio M; Castellano PM; Operto MA; Torres R; Kaufman TS
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5097-101. PubMed ID: 16875818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.
    Hrib NJ; Jurcak JG; Bregna DE; Burgher KL; Hartman HB; Kafka S; Kerman LL; Kongsamut S; Roehr JE; Szewczak MR; Woods-Kettelberger AT; Corbett R
    J Med Chem; 1996 Sep; 39(20):4044-57. PubMed ID: 8831770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-independent C1 activation by E. coli.
    Tenner AJ; Ziccardi RJ; Cooper NR
    J Immunol; 1984 Aug; 133(2):886-91. PubMed ID: 6376630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-stimulated modification of C1-inhibitor by subcomponent C1s of human complement.
    Weiss V; Engel J
    Hoppe Seylers Z Physiol Chem; 1983 Mar; 364(3):295-301. PubMed ID: 6602754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes.
    Loos M; Heinz HP
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():67-74. PubMed ID: 6375257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new simple method for determination of C1-esterase inhibitor activity in plasma.
    Wiman B; Nilsson T
    Clin Chim Acta; 1983 Mar; 128(2-3):359-66. PubMed ID: 6602012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel series of potent and selective small molecule inhibitors of the complement component C1s.
    Subasinghe NL; Ali F; Illig CR; Jonathan Rudolph M; Klein S; Khalil E; Soll RM; Bone RF; Spurlino JC; DesJarlais RL; Crysler CS; Cummings MD; Morris PE; Kilpatrick JM; Sudhakara Babu Y
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3043-7. PubMed ID: 15149641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide.
    Khalil EM; Ojala WH; Pradhan A; Nair VD; Gleason WB; Mishra RK; Johnson RL
    J Med Chem; 1999 Feb; 42(4):628-37. PubMed ID: 10052970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mechanism for the spontaneous activation of the first component of complement, C1, and its regulation by C1-inhibitor.
    Bianchino AC; Poon PH; Schumaker VN
    J Immunol; 1988 Dec; 141(11):3930-6. PubMed ID: 3183385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy.
    Hack CE; Ogilvie AC; Eisele B; Jansen PM; Wagstaff J; Thijs LG
    Prog Clin Biol Res; 1994; 388():335-57. PubMed ID: 7831367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of C1s-C1 inhibitor complexes in plasma by means of an enzyme linked immunosorbent assay.
    Nilsson T; Bäck O
    Clin Exp Immunol; 1985 Apr; 60(1):178-82. PubMed ID: 3874014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.